Involvement	0	11	O
of	12	14	O
PTEN	15	19	B-Gene_or_gene_product
promoter	20	28	B-DNA_domain_or_region
methylation	29	40	O
in	41	43	O
cerebral	44	52	B-Pathological_formation
cavernous	53	62	I-Pathological_formation
malformations	63	76	I-Pathological_formation
.	76	77	O

BACKGROUND	79	89	O
AND	90	93	O
PURPOSE	94	101	O
:	101	102	O
Cerebral	103	111	B-Pathological_formation
cavernous	112	121	I-Pathological_formation
malformations	122	135	I-Pathological_formation
(	136	137	O
CCMs	137	141	B-Pathological_formation
)	141	142	O
are	143	146	O
prevalent	147	156	O
cerebral	157	165	B-Pathological_formation
vascular	166	174	I-Pathological_formation
lesions	175	182	I-Pathological_formation
involving	183	192	O
aberrant	193	201	O
angiogenesis	202	214	O
.	214	215	O

However	216	223	O
,	223	224	O
the	225	228	O
underlying	229	239	O
mechanism	240	249	O
is	250	252	O
poorly	253	259	O
understood	260	270	O
.	270	271	O

Phosphatase	272	283	B-Gene_or_gene_product
and	284	287	I-Gene_or_gene_product
tension	288	295	I-Gene_or_gene_product
homolog	296	303	I-Gene_or_gene_product
deleted	304	311	I-Gene_or_gene_product
on	312	314	I-Gene_or_gene_product
chromosome	315	325	I-Gene_or_gene_product
10	326	328	I-Gene_or_gene_product
(	329	330	O
PTEN	330	334	B-Gene_or_gene_product
)	334	335	O
,	335	336	O
a	337	338	O
tumor	339	344	B-Pathological_formation
suppressor	345	355	O
,	355	356	O
is	357	359	O
frequently	360	370	O
deficient	371	380	O
in	381	383	O
various	384	391	O
pathologies	392	403	O
due	404	407	O
to	408	410	O
mutation	411	419	O
or	420	422	O
epigenetic	423	433	O
alterations	434	445	O
.	445	446	O

PTEN	447	451	B-Gene_or_gene_product
promoter	452	460	B-DNA_domain_or_region
hypermethylation	461	477	O
is	478	480	O
a	481	482	O
major	483	488	O
epigenetic	489	499	O
silencing	500	509	O
mechanism	510	519	O
leading	520	527	O
to	528	530	O
activation	531	541	O
of	542	544	O
angiogenesis	545	557	O
in	558	560	O
tumors	561	567	B-Pathological_formation
.	567	568	O

The	569	572	O
present	573	580	O
study	581	586	O
aimed	587	592	O
to	593	595	O
investigate	596	607	O
whether	608	615	O
PTEN	616	620	B-Gene_or_gene_product
promoter	621	629	B-DNA_domain_or_region
methylation	630	641	O
was	642	645	O
involved	646	654	O
in	655	657	O
CCMs	658	662	B-Pathological_formation
.	662	663	O

METHODS	664	671	O
:	671	672	O
PTEN	673	677	B-Gene_or_gene_product
promoter	678	686	B-DNA_domain_or_region
methylation	687	698	O
was	699	702	O
detected	703	711	O
in	712	714	O
surgical	715	723	O
specimens	724	733	O
of	734	736	O
CCMs	737	741	B-Pathological_formation
(	742	743	O
n	743	744	O
=	744	745	O
69	745	747	O
)	747	748	O
by	749	751	O
methylation	752	763	O
-	763	764	O
specific	764	772	O
polymerase	773	783	O
chain	784	789	O
reaction	790	798	O
.	798	799	O

The	800	803	O
methylation	804	815	O
status	816	822	O
was	823	826	O
correlated	827	837	O
to	838	840	O
the	841	844	O
clinical	845	853	O
manifestations	854	868	O
and	869	872	O
to	873	875	O
PTEN	876	880	B-Gene_or_gene_product
expression	881	891	O
,	891	892	O
which	893	898	O
was	899	902	O
analyzed	903	911	O
by	912	914	O
both	915	919	O
Western	920	927	O
blot	928	932	O
and	933	936	O
immunohistochemistry	937	957	O
.	957	958	O

To	959	961	O
investigate	962	973	O
the	974	977	O
endothelial	978	989	B-Cell
proliferation	990	1003	O
and	1004	1007	O
the	1008	1011	O
potential	1012	1021	O
signaling	1022	1031	O
pathways	1032	1040	O
affected	1041	1049	O
by	1050	1052	O
PTEN	1053	1057	B-Gene_or_gene_product
methylation	1058	1069	O
,	1069	1070	O
proliferating	1071	1084	B-Gene_or_gene_product
cell	1085	1089	I-Gene_or_gene_product
nuclear	1090	1097	I-Gene_or_gene_product
antigen	1098	1105	I-Gene_or_gene_product
as	1106	1108	O
well	1109	1113	O
as	1114	1116	O
phosphor	1117	1125	B-Gene_or_gene_product
-	1125	1126	I-Gene_or_gene_product
Akt	1126	1129	I-Gene_or_gene_product
and	1130	1133	O
phosphor	1134	1142	B-Gene_or_gene_product
-	1142	1143	I-Gene_or_gene_product
Erk1	1143	1147	I-Gene_or_gene_product
,	1147	1148	I-Gene_or_gene_product
2	1148	1149	I-Gene_or_gene_product
were	1150	1154	O
detected	1155	1163	O
by	1164	1166	O
immunofluorescence	1167	1185	O
and	1186	1189	O
Western	1190	1197	O
blot	1198	1202	O
,	1202	1203	O
respectively	1204	1216	O
,	1216	1217	O
in	1218	1220	O
CCM	1221	1224	B-Pathological_formation
specimens	1225	1234	O
.	1234	1235	O

RESULTS	1236	1243	O
:	1243	1244	O
Methylation	1245	1256	O
-	1256	1257	O
specific	1257	1265	O
polymerase	1266	1276	O
chain	1277	1282	O
reaction	1283	1291	O
revealed	1292	1300	O
PTEN	1301	1305	B-Gene_or_gene_product
promoter	1306	1314	B-DNA_domain_or_region
methylation	1315	1326	O
in	1327	1329	O
15	1330	1332	O
.	1332	1333	O
9	1333	1334	O
%	1334	1335	O
CCMs	1336	1340	B-Pathological_formation
.	1340	1341	O

Strikingly	1342	1352	O
,	1352	1353	O
5	1354	1355	O
of	1356	1358	O
6	1359	1360	O
familial	1361	1369	O
CCMs	1370	1374	B-Pathological_formation
showed	1375	1381	O
PTEN	1382	1386	B-Gene_or_gene_product
promoter	1387	1395	B-DNA_domain_or_region
methylation	1396	1407	O
(	1408	1409	O
83	1409	1411	O
.	1411	1412	O
3	1412	1413	O
%	1413	1414	O
)	1414	1415	O
,	1415	1416	O
which	1417	1422	O
was	1423	1426	O
significantly	1427	1440	O
higher	1441	1447	O
than	1448	1452	O
in	1453	1455	O
sporadic	1456	1464	O
cases	1465	1470	O
(	1471	1472	O
9	1472	1473	O
.	1473	1474	O
4	1474	1475	O
%	1475	1476	O
;	1476	1477	O
P	1478	1479	O
<	1479	1480	O
0	1480	1481	O
.	1481	1482	O
001	1482	1485	O
)	1485	1486	O
.	1486	1487	O

In	1488	1490	O
addition	1491	1499	O
,	1499	1500	O
PTEN	1501	1505	B-Gene_or_gene_product
promoter	1506	1514	B-DNA_domain_or_region
methylation	1515	1526	O
appeared	1527	1535	O
more	1536	1540	O
frequently	1541	1551	O
in	1552	1554	O
multiple	1555	1563	O
CCMs	1564	1568	B-Pathological_formation
,	1568	1569	O
including	1570	1579	O
familial	1580	1588	O
cases	1589	1594	O
(	1595	1596	O
46	1596	1598	O
.	1598	1599	O
7	1599	1600	O
%	1600	1601	O
)	1601	1602	O
,	1602	1603	O
than	1604	1608	O
that	1609	1613	O
in	1614	1616	O
single	1617	1623	O
-	1623	1624	O
lesioned	1624	1632	O
CCMs	1633	1637	B-Pathological_formation
(	1638	1639	O
11	1639	1641	O
.	1641	1642	O
8	1642	1643	O
%	1643	1644	O
;	1644	1645	O
P	1646	1647	O
<	1647	1648	O
0	1648	1649	O
.	1649	1650	O
05	1650	1652	O
)	1652	1653	O
.	1653	1654	O

Immunostaining	1655	1669	O
and	1670	1673	O
Western	1674	1681	O
blot	1682	1686	O
revealed	1687	1695	O
a	1696	1697	O
more	1698	1702	O
significant	1703	1714	O
PTEN	1715	1719	B-Gene_or_gene_product
downregulation	1720	1734	O
in	1735	1737	O
PTEN	1738	1742	B-Gene_or_gene_product
-	1742	1743	O
methylated	1743	1753	O
CCMs	1754	1758	B-Pathological_formation
in	1759	1761	O
comparison	1762	1772	O
to	1773	1775	O
PTEN	1776	1780	B-Gene_or_gene_product
-	1780	1781	O
unmethylated	1781	1793	O
CCMs	1794	1798	B-Pathological_formation
.	1798	1799	O

Reduced	1800	1807	O
PTEN	1808	1812	B-Gene_or_gene_product
expression	1813	1823	O
was	1824	1827	O
inversely	1828	1837	O
correlated	1838	1848	O
to	1849	1851	O
the	1852	1855	O
expression	1856	1866	O
of	1867	1869	O
proliferating	1870	1883	B-Gene_or_gene_product
cell	1884	1888	I-Gene_or_gene_product
nuclear	1889	1896	I-Gene_or_gene_product
antigen	1897	1904	I-Gene_or_gene_product
and	1905	1908	O
to	1909	1911	O
the	1912	1915	O
activation	1916	1926	O
of	1927	1929	O
Erk1	1930	1934	B-Gene_or_gene_product
,	1934	1935	O
2	1935	1936	B-Gene_or_gene_product
,	1936	1937	O
but	1938	1941	O
not	1942	1945	O
of	1946	1948	O
Akt	1949	1952	B-Gene_or_gene_product
.	1952	1953	O

CONCLUSIONS	1954	1965	O
:	1965	1966	O
We	1967	1969	O
reported	1970	1978	O
here	1979	1983	O
for	1984	1987	O
the	1988	1991	O
first	1992	1997	O
time	1998	2002	O
the	2003	2006	O
involvement	2007	2018	O
of	2019	2021	O
PTEN	2022	2026	B-Gene_or_gene_product
promoter	2027	2035	B-DNA_domain_or_region
methylation	2036	2047	O
in	2048	2050	O
CCMs	2051	2055	B-Pathological_formation
,	2055	2056	O
particularly	2057	2069	O
in	2070	2072	O
familial	2073	2081	O
CCMs	2082	2086	B-Pathological_formation
,	2086	2087	O
suggesting	2088	2098	O
this	2099	2103	O
epigenetic	2104	2114	O
alteration	2115	2125	O
as	2126	2128	O
a	2129	2130	O
potential	2131	2140	O
pathomechanism	2141	2155	O
of	2156	2158	O
CCMs	2159	2163	B-Pathological_formation
.	2163	2164	O

The	2165	2168	O
identification	2169	2183	O
of	2184	2186	O
Erk1	2187	2191	B-Gene_or_gene_product
,	2191	2192	O
2	2192	2193	B-Gene_or_gene_product
as	2194	2196	O
triggered	2197	2206	O
signaling	2207	2216	O
in	2217	2219	O
the	2220	2223	O
lesions	2224	2231	B-Pathological_formation
may	2232	2235	O
be	2236	2238	O
valuable	2239	2247	O
for	2248	2251	O
the	2252	2255	O
development	2256	2267	O
of	2268	2270	O
effective	2271	2280	O
therapy	2281	2288	O
for	2289	2292	O
this	2293	2297	O
disease	2298	2305	O
.	2305	2306	O

